Want to see CLB full AI Analyst Report?
Top Page
Core Laboratories
(NYSE:CLB)
Select Model
Select Model
Rating:61Neutral
Price Target:
$11.50
▼(-29.32% Downside)
Action:Reiterated
Date:06/25/26
Overall score reflects solid but stressed fundamentals: improved balance sheet and acceptable profitability are offset by a sharp TTM revenue decline and only moderate cash conversion. Technicals are a major drag with a clear downtrend and very weak momentum, while valuation (P/E ~16.5 and ~3.7% yield) provides partial support. Earnings call signals modest Q2 improvement, but disruption-driven uncertainty and recent margin compression keep the outlook constrained.
Positive Factors
Proprietary technology adoption
Core Labs’ proprietary diagnostics and completion products (GTX, FLOWPROFILER, RF-safe detonators, PackScan) drive technical differentiation. Durable product adoption creates higher switching costs, repeat fee-for-service demand and a platform for upselling digital/AI services across multi-year field programs.
Negative Factors
Material revenue decline
A sharp TTM revenue drop and recent sequential declines indicate weakened upstream activity and demand sensitivity. Persistent lower volumes compress absorption of fixed lab and manufacturing costs, threatening near-term utilization and making revenue recovery a multi-quarter process dependent on upstream capex trends.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary technology adoption
Core Labs’ proprietary diagnostics and completion products (GTX, FLOWPROFILER, RF-safe detonators, PackScan) drive technical differentiation. Durable product adoption creates higher switching costs, repeat fee-for-service demand and a platform for upselling digital/AI services across multi-year field programs.
Read all positive factors
Core Laboratories Key Performance Indicators (KPIs)
Any
Revenue By Segment
Shows how different business segments contribute to overall revenue, highlighting which areas drive growth and profitability for Core Laboratories.
Shows how different business segments contribute to overall revenue, highlighting which areas drive growth and profitability for Core Laboratories.
Data provided by:
The Fly
The FlyCore Laboratories (CLB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$537.03M
Dividend Yield0.24%
Average Volume (3M)411.26K
Price to Earnings (P/E)17.6
Beta (1Y)1.17
Revenue Growth1.34%
EPS Growth12.50%
CountryUS
Employees3,400
SectorEnergy
Sector Strength52
IndustryOil & Gas Equipment & Services
Share Statistics
EPS (TTM)0.65
Shares Outstanding46,096,684
10 Day Avg. Volume423,711
30 Day Avg. Volume411,263
Financial Highlights & Ratios
PEG Ratio15.79
Price to Book (P/B)2.80
Price to Sales (P/S)1.42
P/FCF Ratio33.00
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit7.18
Enterprise Value/Ebitda9.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)$517.86M
Core Laboratories Business Overview & Revenue Model
Company Description
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly seg...
How the Company Makes Money
Core Laboratories makes money by selling specialized technical services and related products to oil and gas companies, with revenue primarily generated on a fee-for-service/project basis and, in some cases, through ongoing service arrangements tie...
Core Laboratories Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 29, 2026
Earnings Call Sentiment Negative
The call mixed clear operational and technological strengths (notable product wins, digital data progress, continued shareholder returns and a constructive multi‑year market outlook) with acute near-term headwinds. Q1 showed meaningful sequential revenue declines, sharp margin compression and steep earnings deterioration driven by the Middle East conflict, Russia/Ukraine disruptions, severe weather and higher costs—offset only partially by product/diagnostic demand in select regions and ongoing capital returns. Management expects modest sequential improvement in Q2 but the near-term outlook is still clouded by geopolitical and operational uncertainty.Positive Updates
Revenue and Seasonal Context
Q1 revenue was $121.8M, down 12% sequentially and down 1% year-over-year; management notes typical seasonal Q4→Q1 decline but emphasizes underlying demand pockets (e.g., Gulf of Mexico diagnostics) that partially offset softer regions.
Negative Updates
Significant Sequential Revenue and Margin Declines
Total revenue fell 12% sequentially to $121.8M (down 1% YoY). Reservoir Description revenue declined 11% QoQ to $82M (flat YoY). Production Enhancement revenue fell ~13% QoQ (also reported as down 7% YoY) to $40M. Operating margins compressed materially across segments.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and Seasonal Context
Q1 revenue was $121.8M, down 12% sequentially and down 1% year-over-year; management notes typical seasonal Q4→Q1 decline but emphasizes underlying demand pockets (e.g., Gulf of Mexico diagnostics) that partially offset softer regions.
Read all positive updates
Company Guidance
Core Lab guided Q2 2026 revenue of $123.0M–$131.0M, with segment guidance of Reservoir Description revenue $77.5M–$82.5M (operating income $3.5M–$5.4M) and Production Enhancement revenue $45.5M–$48.5M (operating income $2.8M–$4.7M), implying consolidated operating income of $6.4M–$10.2M (roughly a 7% operating margin) and EPS of $0.06–$0.12; the guidance excludes FX gains/losses and assumes a 25% effective tax rate. Management reiterated FY-2026 G&A ex-items of approximately $42M–$45M, capital expenditures (excluding insurance-covered U.K. rebuild) of $15M–$18M (historically ~2–4% of revenue), expects manufacturing absorption to align with projected product sales, and said it will continue to deploy free cash to the dividend and opportunistic share repurchases (Q1 free cash flow was $0.5M; cash $22.8M; net debt $94.2M; leverage ~1.2x).Core Laboratories Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
72
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 524.73M | 526.52M | 523.85M | 509.79M | 489.74M | 470.25M |
| Gross Profit | 93.61M | 94.28M | 88.37M | 94.05M | 78.92M | 83.84M |
| EBITDA | 72.35M | 71.12M | 73.51M | 70.42M | 58.69M | 63.78M |
| Net Income | 29.03M | 29.67M | 31.40M | 36.67M | 19.45M | 19.73M |
Balance Sheet | ||||||
| Total Assets | 587.73M | 584.01M | 590.41M | 586.39M | 578.35M | 580.85M |
| Cash, Cash Equivalents and Short-Term Investments | 22.82M | 22.70M | 19.16M | 15.12M | 15.43M | 17.70M |
| Total Debt | 167.84M | 164.02M | 180.14M | 215.38M | 222.39M | 250.26M |
| Total Liabilities | 312.58M | 311.80M | 332.67M | 356.59M | 389.40M | 419.85M |
| Stockholders Equity | 268.89M | 265.99M | 251.99M | 224.81M | 184.26M | 156.45M |
Cash Flow | ||||||
| Free Cash Flow | 18.94M | 22.59M | 43.36M | 14.21M | 14.74M | 23.04M |
| Operating Cash Flow | 35.10M | 37.18M | 56.39M | 24.79M | 24.96M | 36.58M |
| Investing Cash Flow | -6.57M | -2.23M | -6.39M | -6.65M | -3.86M | -10.22M |
| Financing Cash Flow | -27.40M | -31.25M | -45.96M | -18.45M | -23.38M | -22.46M |
Core Laboratories Technical Analysis
Negative
16.27
Price Trends
13.71
Negative
15.37
Negative
15.44
Negative
Market Momentum
-0.83
Positive
30.79
Neutral
11.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Negative. The current price of 16.27 is above the 20-day moving average (MA) of 12.34, above the 50-day MA of 13.71, and above the 200-day MA of 15.44, indicating a bearish trend. The MACD of -0.83 indicates Positive momentum. The RSI at 30.79 is Neutral, neither overbought nor oversold. The STOCH value of 11.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLB.
Core Laboratories Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $850.89M | 27.93 | 28.83% | ― | 24.72% | 72.35% | |
65 Neutral | $15.17B | 7.61 | 4.09% | 5.20% | 3.87% | -62.32% | |
61 Neutral | $537.03M | 17.64 | 10.74% | 0.24% | 1.34% | 12.50% | |
60 Neutral | $1.76B | -124.35 | -1.43% | ― | -15.55% | 91.88% | |
57 Neutral | $1.66B | 168.56 | 2.51% | ― | 4.09% | -93.54% | |
54 Neutral | $482.15M | -4.14 | -17.52% | ― | -4.50% | -2286.91% | |
48 Neutral | $1.05B | -2.17 | -53.92% | ― | -18.94% | -69.29% |
* Energy Sector Average
CLB
Core Laboratories
11.65
-0.26
-2.22%
FTK
Flotek
23.52
8.90
60.88%
OIS
Oil States International
8.01
2.54
46.44%
TTI
Tetra Technologies
11.33
7.96
236.20%
PUMP
Propetro Holding
14.34
8.13
130.92%
ACDC
ProFrac Holding
5.81
-2.16
-27.10%
Core Laboratories Corporate Events
Executive/Board ChangesShareholder Meetings
Core Laboratories Shareholders Back Directors, Auditor and Pay
Positive
May 13, 2026
Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, in Houston, Texas, where investors considered director elections, auditor ratification, and executive compensation matters. Shareholders re-elected Class I directors H...
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
Core Laboratories Posts Flat Q1 2026 Results Amid Disruptions
Negative
Apr 29, 2026
Core Laboratories, a Houston-based oilfield services specialist in reservoir description and advanced production enhancement technologies, generated most of its first-quarter 2026 revenue from international and offshore projects, underscoring its ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.